Novira Therapeutics Secures $7.5M; Completes $25M Series A Financing

Novira Therapeutics, Inc., a Radnor, PA-based antiviral drug discovery company, secured $7.5m and completed its $25m Series A financing.

New investor Versant Ventures joined 5AM Ventures and Canaan Partners, which led the first closing of the Series A in August 2012 (read here). In conjunction with this investment, Gianni Gromo M.D ., Ph.D., venture partner with Versant Ventures, joined the company’s board of directors.

Scott M. Rocklage, Ph.D., a managing partner with 5AM  Ventures, and Tim Shannon, M.D., venture partner at Canaan Partners, had joined the board in conjunction with the first close.

Led by Osvaldo Flores , Ph.D., president and chief scientific officer, Novira focuses on the discovery of antiviral therapeutics for the treatment of chronic HBV infection. It develops oral drugs that target the capsid of the virus and offer a treatment option both as monotherapy and in combination with current standards of care.



Join the discussion